Apyx Medical Corporation filings document regulatory disclosures for a surgical aesthetics medical-device issuer. Recent Form 8-K reports cover results of operations, preliminary revenue releases, FDA 510(k) clearance updates for the AYON Body Contouring System, and exhibits tied to company press releases.
The filing record also includes capital-structure and governance disclosures, including an underwritten common stock offering, amendments to the certificate of incorporation, annual meeting voting results, director elections, auditor ratification, executive compensation advisory votes, and related proxy matters.
Apyx Medical Corp (APYX) is the subject of a Schedule 13G reporting group whose members may be deemed to beneficially own 2,280,518 shares, approximately 5.4% of outstanding shares, as of October 27, 2026. Philotimo Fund LP reported 1,425,473 shares and Philotimo Focused Growth & Income Fund reported 855,045. Kanen Wealth Management LLC reported the same 2,280,518 shares through its roles as general partner and investment manager, and David L. Kanen may be deemed to beneficially own those shares through his role as managing member. These figures reflect the same fund-held shares, not additional holdings.
Apyx Medical Corporation (APYX) announced publication in Plastic and Reconstructive Surgery—Global Open of clinical data evaluating Renuvion helium plasma radiofrequency technology and biological markers of skin quality.
The prospective, single-arm post-market study evaluated seven patients undergoing lower rhytidectomy at two U.S. investigational sites; six completed the Day 180 visit. Renuvion was applied to subdermal tissue, with untreated areas serving as internal controls. The study concluded that treatment was well-tolerated and resulted in favorable dermal remodeling, characterized by increased elastin and reduced inflammation without significant fibrosis.
Apyx Medical Corporation held its 2026 Annual Meeting of Stockholders on August 6, 2026. Stockholders elected five directors and ratified RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 29,814,618 votes cast in favor.
Stockholders also approved a non-binding advisory resolution on executive compensation, receiving 21,458,554 votes in favor, and approved the Company’s 2026 Share Incentive Plan, which obtained 16,186,776 votes cast in favor, 2,755,882 votes against, and 3,276,000 abstentions.
Apyx Medical Corporation reported Q2 2026 sales of $13,884 (in thousands), up 22.1% year over year, and six‑month sales of $26,374 (in thousands), up 26.8%. Growth was driven by the Surgical Aesthetics segment, which rose 28.1% in Q2 and 31.7% year to date, helped by AYON Body Contouring, higher handpiece volumes and stronger international generator sales.
Gross margin improved to 63.9% in Q2 and 63.7% for the first half. The company still posted losses: Q2 net loss attributable to stockholders was $3,243 (in thousands), with a six‑month net loss of $5,351 (in thousands), or basic and diluted loss per share of $0.07 and $0.12, respectively. Cash and cash equivalents were $27,617 (in thousands) at June 30, 2026; net cash used in operating activities was $4,062 (in thousands) for the first half.
Apyx carries a $37,500 (in thousands) term loan under its Perceptive Credit Agreement at a 12.0% interest rate and remains in covenant compliance, including Surgical Aesthetics revenue and operating expense targets. The company disclosed ongoing product liability matters with recorded defense cost accruals and a new patent infringement lawsuit filed July 20, 2026, while also highlighting expanded FDA 510(k) clearance for AYON power liposuction and a limited commercial launch started in late June.
Apyx Medical Corporation reported that on August 6, 2026 it issued a press release presenting its results of operations for the second quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 and is incorporated by reference.
The company states that this earnings information is furnished under Item 2.02 of the Exchange Act, rather than filed for purposes of Section 18 or automatically incorporated into other Securities Act or Exchange Act reports unless specifically referenced. The report also identifies a Cover Page Interactive Data File, prepared using Inline XBRL, as Exhibit 104.
On July 24, 2026, Apyx Medical Corporation reported that its Board of Directors reconstituted the membership and chairs of its standing committees.
Following his appointment as Executive Chairman effective June 11, 2026, Stavros Vizirgianakis will not serve on any Board committee. The Board determined that Mr. Waldman, Ms. Baylor-Henry, and Ms. Levine are independent under applicable Nasdaq Global Select Market and SEC rules and that Mr. Waldman qualifies as an audit committee financial expert under SEC regulations.
Royce & Associates reports amended beneficial ownership of Apyx Medical Corporation common stock. The firm beneficially owns 3,274,064 shares, representing 7.81% of the class as of June 30, 2026. It has sole power to vote and dispose of all reported shares and no shared voting or dispositive power.
The shares are held in investment management accounts of clients of Royce & Associates, LP, an indirect majority-owned subsidiary of Franklin Resources, Inc. Royce & Associates states the holdings are maintained in the ordinary course of business, disclaims pecuniary interest and beneficial ownership beyond Rule 13d-3, and indicates the position is not held to change or influence control of Apyx Medical Corporation.
Apyx Medical Corp director Lawrence Waldman reported a routine stock option exercise with tax withholding. On June 30, 2026, a Spousal Lifetime Access Trust associated with him exercised 12,000 stock options at an exercise price of $1.88 per share. Under the net exercise terms, 5,024 shares that would have been issued were instead withheld by the company at a value of $4.49 per share to cover the aggregate exercise price, and 6,976 net shares were issued. Following these transactions, the filing shows 37,563 common shares held directly and 12,314 shares held indirectly through the trust, while the exercised option grant was reduced to zero. The footnotes state the trust is a Spousal Lifetime Access Trust and that Waldman disclaims beneficial ownership of its holdings except for any pecuniary interest.
Apyx Medical Corporation is soliciting proxies for its 2026 Annual Meeting of Stockholders on August 6, 2026, where holders will vote to elect five directors, ratify RSM US LLP as auditor, approve a non-binding say-on-pay resolution, and approve the 2026 Share Incentive Plan.
Stockholders of record at the close of business on June 15, 2026, when 41,912,040 common shares were outstanding, are entitled to vote. The proxy statement also reviews 2025 developments, including FDA 510(k) clearance and commercial launch of the AYON body contouring system, Renuvion’s launch in China, and a November 2025 equity offering of 2,762,431 shares at $3.62 for approximately $9.1 million in net proceeds.
The filing details executive and director compensation, with CEO Charles D. Goodwin’s 2025 total compensation of $1,233,863, an at-risk bonus framework tied to performance, significant stock option grants, and an executive compensation clawback policy. It also highlights governance structures such as a majority-independent board, four standing committees, a lead independent director, a code of ethics, and an insider trading policy.
Apyx Medical Corp Chief Operating Officer Shawn David Roman reported a net stock option exercise through The Roman Family Revocable Trust. On June 15, 2026, he exercised 15,000 stock options at an exercise price of $3.23 per share.
To cover the aggregate exercise price, 10,533 shares of common stock otherwise issuable were withheld by the issuer at a value of $4.60 per share as a tax and exercise-price payment. As a result, 4,467 net shares of common stock were issued to the trust. Following the tax-withholding disposition, the trust held 16,467 shares of Apyx Medical common stock indirectly for the reporting person.